ArticleJournal of the National Cancer Institute. Monographs2024
History of the Surveillance, Epidemiology, and End Results (SEER) Program.
Article in Journal of the National Cancer Institute. Monographs, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Development and validation of a SEER-based auxiliary nomogram for clinical features associated with pulmonary metastasis status in pediatric osteosarcoma.Translational pediatrics · 2026Article
- Cause-specific mortality in a population-level cohort of pancreatic cancer patients following chemotherapy: A SEER-based study.Medicine · 2026Article
- All-Cause and Cause-Specific Mortality by SEER Stage in Gastric Cancer: A Nationwide Population-Based Cohort Study.Journal of clinical medicine · 2026Article
- Association of surgical resection with survival in retroperitoneal leiomyosarcoma based on SEER propensity score matching and machine-learning models.Scientific reports · 2026Article
- Impacts of Neighborhood Persistent Poverty and Socioeconomic Status on Hepatocellular Carcinoma Outcomes: A Large Population-Based Cohort Study.Cancer medicine · 2026Article
- Eligibility and Prognostic Performance of Smoking Duration-Based Versus Pack-Year-Based U.S. National Lung Cancer Screening Criteria Across Racial and Ethnic Groups.Annals of internal medicine · 2026Article
- Risk factors and predictive nomograms for early mortality in patients with thyroid cancer lung metastasis based on the SEER database and a Chinese population study.Gland surgery · 2025Article
- Effects of Hydrocodone Rescheduling on Pain Management Practices Among Older Breast Cancer Patients.Current oncology (Toronto, Ont.) · 2025Article
- Using data for novel discoveries in neuro-oncology research.Journal of neuro-oncology · 2025Review
- Neighborhood level socioeconomic disparities are associated with reduced colorectal cancer survival.Scientific reports · 2025Article
- Machine learning-based prognostic model for human immunodeficiency virus-associated cutaneous T-cell lymphoma: A Surveillance, Epidemiology, and End Results database analysis.The Journal of international medical research · 2025Article
- Systematic curation and analysis of ovarian cancer data across multiple electronic record systems held within the UK National Health Service: a tertiary referral centre experience.ESMO real world data and digital oncology · 2025Article
- A Population-Based Study of Sex Differences in Cardiovascular Disease Mortality Among Adults with Ocular Cancer in the United States, 2000-2021.Current oncology (Toronto, Ont.) · 2025Article
- Breast implant illness and the power of national mandatory reporting.Journal of the National Cancer Institute · 2025Article
- Cancer registries in Pakistan: a scoping review.The Lancet regional health. Southeast Asia · 2025Review
- Geographic differences in early-onset breast cancer incidence trends in the USA, 2001-2020, is it time for a geographic risk score?Cancer causes & control : CCC · 2025Article
- Review
- Pancancer analysis of DNA damage repair gene mutations and their impact on immune regulatory gene expression.Scientific reports · 2025Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The Surveillance, Epidemiology, and End Results (SEER) Program established in 1973 was the first laboratory for experimenting with new methods for cancer data collection and translating the data into population-based cancer statistics. The SEER Program staff have been instrumental in the development of the International Classification of Disease-Oncology and successfully implemented the routine collection of anatomic and prognostic cancer stage at diagnosis. Currently the program consists of 21 central registries that generate cancer statistics covering more than 48% of the US population and an additional 10 research support registries contributing to certain research projects, such as the National Childhood Cancer Registry. In parallel with the geographical expansion, the program built an architecture of methods and tools for population-based cancer statistics, with SEER*Explorer as the most recent online tool for descriptive statistics. In addition, SEER releases annual updates for a comprehensive data product line, which includes SEER*Stat databases with an annual caseload of more than 800 000 incident cases. Furthermore, the program developed a full suite of analytical applications for population-based cancer statistics that include Joinpoint (regression-based trend analysis), DevCan (risk of diagnosis and death), CanSurv (survival models), and ComPrev and PrejPrev (cancer prevalence), among others. The future of the SEER Program is closely aligned to the overall goals of the "war on cancer." The program aims to release longitudinal treatment data coupled with a comprehensive genomic characterization of cancers with a declared goal of decreasing the cancer burden and disparities across a wide spectrum of diseases and communities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.